Word count: 5101

Title: Does the Diabetes Alliance Program Improve Longer-term Health Outcomes of Patients with Type 2 Diabetes Attending Primary Care Practices? A Target Trial Protocol for Emulating a Cluster Trial Using Linked General practice and Tertiary Health Data

Authors: Joshua Aaron Dizon[1,2*], Dr Daniel Barker[1,2], A. Prof Alexis Hure[1,2], A. Prof Christopher Oldmeadow[1,2], Dr Patrick Skippen[1,2], A. Prof Shamasunder Acharya[1,3]

[1]School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, 2308, Australia

[2]Hunter Medical Research Institute, New Lambton Heights, NSW, 2305, Australia

[3] Hunter New England Local Health District, John Hunter Hospital, NSW, Lookout Road, New Lambton Heights 2305, Australia

* Corresponding author.

Joshua Aaron Dizon

Data Sciences

Hunter Medical Research Institute

New Lambton Heights, NSW 2305, Australia

Email: Joshua.Dizon@newcastle.edu.au

Author Contributions: JA, DB, and CO contributed to the statistical analysis plan and statistical rationale described in this article. AH and SA provided clinical rationale for this protocol. All authors were involved in the discussions and editing of the manuscript and provide approval for publication.

Funding: The Diabetes Alliance Program Plus and this work is supported by a philanthropic gift from the Colonial Foundation, administered by the Hunter Medical Research Institute.

Competing interest: None declared.

Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Patient consent for publication: Not applicable.

Key words: causal inference, cluster trial emulation, T2DM, propensity score matching

Acknowledgements: This research was supported by an Australian Government Research Training Program (RTP) Scholars

ABSTRACT

Background:

Effective management of type 2 diabetes remain a challenge for health services in Australia. Rural and remote communities in particular are at a higher risk of diabetes-related complications due to reduced access to specialist services, making the role of general practices all the more important in the provision of diabetes care. Integrated care targeted around increasing capacity to rural general practices in the treatment of type 2 diabetes may reduce the disparity in health outcomes among rural and remote patients suffering from type-2 diabetes. This protocol aims to describe a causal approach for the evaluation of a specialist-led integrated model of care delivered to general practices using large administrative health data.

Methods and analysis:

This will be an observational cohort study using linked general practice and hospital data from the Lumos program. This protocol adopts the target trial framework approach described by Hernan et al and the estimands framework proposed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). We describe the data structure and statistical analysis plan that would be required for causal inferences. The target causal estimand is the effect of the Diabetes Alliance Program Plus integrated care intervention, among general practice active-attending adult patients with current and new diagnoses of type 2 diabetes, on three-year hospitalisation rates wherein type 2 diabetes is the principal diagnosis. Causal effect estimates and the precision in these estimates will be quantified.

Ethics and dissemination:

The Diabetes Alliance Program Plus has ethics approval from the Hunter New England Human Research Ethics Committee (2024/ETH01649), with approval registered with the University of Newcastle (R-2024-0073). The Lumos data asset is also ethically approved by the Population Health Services Research Ethics Committee (PHSREC; 2019/ETH00660), and DAP+ has received approval by their Governance Committee for the evaluation in this protocol. The analysis and interpretation of the results will be contingent of the quality of the observational data. Findings will be disseminated to local stake holders and submitted to scientific peer-reviewed journals.

Data statement:

The data will not be made publicly available due to privacy, ethical, and data governance restrictions.

ARTICLE SUMMARY

Strengths and limitations of this study:

- This protocol incorporates design principles from randomised trials to the analysis plan of a large health-service data asset, which allowed us to construct a clear target causal estimand.
- This approach describes a novel two-step propensity matching approach to account for cluster-level confounding in observational analyses in order to create a statistical analogue of cluster randomisation.

- The statistical methods described in this protocol describes an appropriate method comparing individual-level effects across clusters, in cases where an intervention results in clusters of all-treated and all-not-treated individuals.

- The implementation of this protocol will be limited by the availability and quality of data collection in the proposed data asset.

INTRODUCTION

Approximately 1.2 million (4.6%) of people were living with type 2 diabetes mellitus (T2DM) in Australia in 2021 with T2DM prevalence increasing with level of remoteness and socioeconomic disadvantage, and many cases likely remain undiagnosed [1]. In particular, the prevalence of diabetes among adults in Australia's Hunter region was more than twice the national average in 2019, at approximately 13% [2]. T2DM is associated with long-term health complications [1,3], increased economic and quality-of-life burdens [4], increased burden to health services and institutions [1], and premature mortality, all of which may be further exacerbated in the presence of chronic poor management of the disease.

Though primary care plays a major front-line role in diabetes management in Australia, it is estimated that 37% of patients with diabetes still do not receive the appropriate level of care from their general practitioners [5]. Contextual barries for patients in their management of diabetes include direct treatment costs such as from accessing general practitioners and medication costs, as well as time costs associated with seeking treatment[6]. Likewise, general practitioners may encounter lack of process systems in place within general practice that allow tracking of patients with diabetes and their visits, and lack of continuous medical education in diabetes management as barriers to providing best diabetes care to their patients [6].

In regional, rural, and remote Australia, the proportion of patients with diabetes that meet target guidelines for BMI and serum lipids is lower than that of the urban population [7]. The rate of diabetes related mortality increases with rurality and can be as much as 2.2-fold higher in remote and very remote areas compared to major cities [1]. The role of primary care providers may play a more critical role in diabetes care compared to urban communities, as these communities are less likely to have access to specialist services.

Intervention and support for primary health practitioners to provide the best standard of care for diabetes may result in better glycaemic control among their patients with diabetes. This, in turn, could reduce health complications associated with diabetes, thus reducing the burden of disease on health services and importantly improve the short and long-term health outcomes for patients. While it may be difficult to obtain objective measures of the quality of diabetes care an individual receives, laboratory measurements of diabetes metabolic markers such as HbA1c, blood lipids, and urinary albumin may act as surrogate objective measures of diabetes management in a group or population level[8]. The target levels and frequency of these metabolic marker measurements are set out in Royal Australasian College of General Practitioners' (RACGP) diabetes annual cycle of care guidelines [9,10]. Thus, assessing the extent that patients meet these guidelines could be used in evaluating the effectiveness of interventions aimed at improving the provision of diabetes care at the provider level.

The pilot study performed by the Diabetes Alliance Program Plus (DAP+), formerly the Diabetes Alliance Program in 2015 [11] involves one such intervention. The initial Diabetes Alliance Program was a partnership between HNELHD and the HNECCPHN, from 2015 to 2022. From 2023 the partnership was expanded to the Diabetes Alliance Program Plus (DAP+) and included the University of Newcastle and Hunter Medical Research Institute. The DAP+ intervention targeted macro-processes involved in diabetes care and aimed to build capacity in primary care practices in better managing diabetes in rural areas of the Hunter and New England region in NSW, Australia. It consisted of a four-part quality-improvement program that included i.) whole practice diabetes data analysis and performance feedback; ii. specialist-led case-conferencing sessions in general practice; iii. structured educational programs for primary

care clinicians; and iv. regional aggregate T2DM-related data monitoring. It demonstrated improvements in patients' HbA1c, systolic blood pressure, and cardiovascular risk over a 6-month follow-up. The intervention was well-received by both health providers and patients with diabetes [12] [13]. These results may indicate a short-term general improvement in quality of provisioned diabetes care within the exposed practices. However, whether the effects of the DAP+ intervention affect longer-term outcomes remains unclear. Sustained improvements in these metabolic markers, through active medical management, may result in greater diabetes control and may reduce T2DM-related complications over the longer term.

Improvements to diabetes-related health outcomes may also reduce the impact of diabetes on both individuals and the Australian government. In 2005, per-person age- and sex-adjusted total direct costs for diabetes were A$3806. This was approximately double that of the per-person A$1900 for normal glucose tolerance. Likewise, government subsidies covered A$5379 per-person for diabetes, and A$3362 per-person for normal glucose tolerance. Nationally, the annual total excess cost of diabetes was A$4.5 billion[14]. Notwithstanding economic impacts, the burden-of-disease from T2DM, measured as disability-adjusted life years (DALY), was 4.7 per 1000 population. That is, 4.7 years of healthy life per 1000 people, and 124,000 DALY for the entire 2023 population, were lost due to T2DM [1].

While a randomised controlled trial (RCT) may be ideal to investigate questions of intervention effectiveness, they may not always be feasible, and findings from these may not translate directly into real world practice due external generalisability issues. Additionally, conducting an RCT for the longer-term evaluation of DAP+ is no longer practical as DAP+, since its initial pilot study that was not designed for a long-term evaluation, has already reached wider implementation and is currently operating business-as-usual across the Hunter New England Local Health District. Instead, the research framework called target trial emulation [15], which allows identification of causal effects using observational data will be used in lieu of an RCT. This protocol will outline an emulated trial that is to be conducted on a large administrative health data set for investigating the effectiveness of the DAP+ intervention on longer-term health outcomes.

The approach described in this protocol aims to allow estimation of the causal effect of the DAP+ cluster intervention on longer-term T2DM health outcomes, particularly on T2DM-related hospital admissions, rate of T2DM-related ED presentations, T2DM-related hospital length-of-stay, T2DM-related lower limb loss, and metabolic markers, in people with T2DM. Secondly, the approach described aims to outline an extension of the trial emulation methods to allow emulation of cluster trials. Lastly, this approach aims to demonstrate the feasibility and utility of the Lumos data asset in the conduct of investigations that evaluate pragmatic interventions.

METHODS AND ANALYSIS

Target trial emulation

Target trial emulation refers to the process of implementing RCT design principles to the analysis of observational data. This instils the observational analysis with the features of the hypothetical trial it is derived from, with the purpose of improving inferences and reducing bias in the observational analysis. Like RCT protocols, the protocol of the target trial defines the eligibility criteria, treatment strategies, treatment assignment, follow-up periods, outcomes, and a statistical analysis plan. The target trial protocol also defines the causal contrasts of interest i.e., the observational analogue of the intention-to-treat or the per-protocol effect [15]. Additional

to key RCT design principles, the target trial protocol also requires explicit definitions of the baseline (index date/start of follow-up), potential confounder variables at baseline, potential post-baseline confounders (time-varying covariates), and important sub-group variables, as appropriate.

In this approach, the target trial framework is applied to emulate a cluster trial using the Lumos data asset and outlines the key protocol components that emulate the eligibility criteria, treatment strategy, treatment assignment, follow-up period, outcomes of interest, causal contrast and analysis plan.

Data sources and structure

This approach uses the Lumos data asset, an ethically approved program that securely links encoded data from general practices to other health data in NSW, including hospital, ambulance, emergency department, and mortality data and operates under strict data governance processes. It operates in partnership between NSW Primary Health Networks, general practices, and the NSW Ministry of Health (MoH) [16].

Lumos will be used to identify general practices and their patients for inclusion. General practices that provide voluntary informed consent to Lumos permits all individual patient records from the consenting general practice to be linked to their respective statewide health service data, providing same-individual record linkage of primary care data from general practices with data from various health sectors. This is made possible by the waiver granted to the Lumos program of the usual requirement to obtain individual patient consent for secondary use of personal health information providing that use of the data falls within the Lumos Governance Framework [16]. For authorised collaborators, access to the Lumos data asset is permitted through a cloud-based Secure Analytics Health Environment (SAPHE) platform.

The general practice data captured by Lumos consists of patient encounters, chronic disease, immunisation, and medication history, pathology results, and Medicare billing codes as recorded in the general practice record. Together with other statewide linked data sets, particularly secondary and tertiary care access data, the Lumos data asset provides a comprehensive overview of patients' access to health care services in NSW.

The use of the Lumos data asset is ethically approved for use in the provision of information that support public health programs in NSW in areas such as chronic condition management and early intervention. Its use is ethically approved for improving the identification, and reduction, of preventable emergency department demand, unplanned hospital presentations, and readmission rates. Therefore, the use of Lumos data is restricted to purposes for the planning, funding, management, and evaluation of health services[16].

Target trial specification

A comparative summary of the ideal randomised trial and its emulated target trial is presented in Table 1.

Table 1: Summary of the design features of the target trial protocol for the Diabetes Alliance Program (DAP+) using the LUMOS linked data.

Protocol component	Target trial specification	Target trial emulation
Eligibility	General practices that consent to	Same. Eligible patients will be

criteria	receiving the Diabetes Alliance Program (the intervention). Adults with a diagnosis of T2DM and actively attend general practices. Active patients are defined as having 3 or more visits to general practices in the past 2 years. Exclusion criteria (patients): Pregnant women Diabetes diagnoses other than T2DM.	identified from eligible practices in the Lumos data asset.

Treatment strategies	1. Receive Diabetes Alliance integrated care intervention (practice level):
	    1a. Specialist-led case conferences in general practices with adult patients with T2DM.
	    1b. Whole general practices diabetes data analysis and feedback.
	    1c. Educational programs for primary care physicians; or,
	
	2. Usual care.
	
	Continue with assigned treatment exposure during follow-up.
		Same

Assignment procedures	Practices will be randomly assigned to receive the Diabetes Alliance Program (intervention) or continue with usual care. Practices will not be blinded to the intervention.	Randomisation via propensity matching will be assumed conditional on available covariates identified as important confounders using causal directed acyclic graphs. Matching of practices will be performed many-to-one (treated practices can match with multiple control practices) and matching of individuals within matched practices will be performed one-to-one without replacement. Calendar time, Modified Monash Model and IRSAD aggregates, and high-servicing status at the cluster level will be accounted for.

		Calendar time (at baseline), age in continuous years (at baseline), comorbidities, gender, Modified Monash Model, age at first record of T2DM, high-servicing status, and IRSAD will be accounted for at the individual level.
Follow-up period	Follow-up begins at the date following the first case conferencing in each site and continues for until death, loss-to-follow-up, or administrative end of follow-up (5 years from baseline), whichever occurs first.	Follow-up will be defined separately for each matched individual. Follow-up begins on the date of an eligible general practice consultation and continues until death or administrative end of follow-up (5 years from baseline), whichever occurs first.
Outcomes	Outcomes are assessed at the individual level; at 1, 3, and 5 years from first exposure to DAP+: • Rates of admissions with T2DM as principal diagnosis. o Distribution of reasons for admissions • Rates of ED presentations related to T2DM. • Hospital length of stay • Mean HbA1c (% or mmol/mol). • Mean measurements of lipids • Rates of HbA1c, UAC, and GFR tests per patient • Rates of BP measurements per patient as measured in the general practice.	Same
Causal contrasts	ITT (primary) and Per-protocol effect	Same
Estimands	ITT: Average treatment effect on the treated among eligible individuals visiting DAP+ practices (effect of at least one exposure to DAP+ enhanced care) Per-protocol: Average treatment effect on the treated among eligible individuals visiting DAP+ practices, who do not switch general practices and remain active patients (effect of consistent exposure to DAP+ enhanced care)	Same

Analysis plan	Summary of patient baseline characteristics. General estimating equations (GEE) models: • Poisson/negative binomial GEEs for rates of hospital admissions, ED presentation, and hospital length of stay. • Robust Poisson regression for risk of T2DM-related lower limb amputations • Linear GEEs for differences in metabolic marker measurements	Same

Population and eligibility

The target population of this trial emulation are residents of NSW, Australia, with a clinical diagnosis of T2DM and attending a Lumos-consented general practices from the 1st of January 2015. Eligibility will be determined dynamically. Patients who are, or become, aged 18 or over with a current diagnosis of T2DM and is an active patient will be deemed eligible. Patients who were not determined to be eligible at a given time point may become eligible at a later point when the eligibility criteria are met.

The eligibility criteria were intended to select patients who have existing T2DM diagnosis prior to January 2015 as well as new diagnosis of T2DM onwards, within the constraints of the Lumos data asset.

Recruitment and follow-up period

Ongoing recruitment (i.e., inclusion to the observational target trial) will be from the 1st of January 2015 and onwards. Eligible patients of DAP+-enabled practices will enter the study on the date of their earliest eligible visit (index date) after the practice has received the intervention.

Propensity-matched controls will be chosen among patients that fulfill the eligibility criteria and attend a non-DAP+ practice outside of the Hunter New England Local Health District. Treated and control units will be matched such that the matched dyad will have a difference of no more than 28 calendar days between their index dates. Patients will exit the study at either completion of follow-up (5 years from index date); death, or administrative censoring, whichever occurs first. Baseline variables will be measured at the index date and up to two years prior.

Exposures

The treatment is DAP+-enhanced care, and the relevant comparator is standard care in general practice. Exposure to treatment is defined as the first attendance after meeting individual eligibility to a DAP+-enabled practice. Exposure to standard care is defined as attendance to a non-DAP+ practice after meeting individual eligibility.

The primary outcome is hospitalisations with T2DM as principal diagnosis after 3 years from the index date. T2DM-related admissions will be determined within the linked NSW Admitted Patient Data Collection (APDC) data set. International Classification of Disease 10th revision (ICD-10) codes will be used in determining whether hospitalisations have T2DM as a principal diagnosis. Unique T2DM-related episodes-of-care will constitute a single count of T2DM-related hospitalisation, and the total number of counts will be obtained for 1, 3, and 5 years after the index date.

The secondary outcomes are length-of-stay of T2DM-related admissions, T2DM-related ED presentations, T2DM-related lower limb loss, measurements of metabolic markers related to T2DM, compliance with the frequency of diabetes tests, and all-cause mortality.

T2DM-related admissions length-of-stay will be obtained from the APDC data set for each unique T2DM-related episode-of-care.

Unique T2DM-related ED episodes-of-care as recorded in the Emergency Department Data Collection (EDDC) will constitute a single count of T2DM-related ED episode-of-care, and the total number of counts will be obtained for 1, 3, and 5 years after the index date. Whether an ED episode-of-care is related to T2DM will be determined using the ICD code or SNOMED-CT code corresponding to that episode-of-care.

T2DM-related lower limb loss will be determined within the APDC data set. The specification of the indicator for this outcome will follow the Australian Institute of Health and Welfare's (AIHW) specification[17]. The indicator will be defined as an observation with both an ICD code corresponding to T2DM in conjunction with an Australian Classification of Health Interventions (ACHI) within the APDC data set. Analysis of this outcome will be limited to T2DM patients who have not had any lower limb amputations at baseline.

Measurements of metabolic markers related to T2DM will be obtained from the General Practice Electronic Health Record (GPEHR) data set within Lumos.

The diabetes annual cycle of care guidelines[9] recommends that body weight, waist, BMI, and blood pressure are monitored every 6 months; HbA1c every 6-12 months; and total cholesterol, lipid profile, uACR and eGFR rate every 12 months. For each measure, compliance will be defined for each month from the index date, and the total proportion of months in compliance will be calculated at 1, 3, and 5 years from the index date.

All-cause mortality will be determined within the Registry of Births, Marriages, and Deaths (RBDM) data set within Lumos. Patients with observations in the RBDM will be considered as experiencing all-cause mortality. These patients will have their survival status defined as surviving up until the date-of-death and deceased otherwise. Patients with no records in the RBDM will be defined as surviving.

Clarifying the estimands

An estimand is the description of the treatment effect a study seeks to quantify. The use of estimands can help clarify the research question and helps in identifying the correct study methods that can be used to answer these questions. We used the International Council for the Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (ICH E9(R1)) [18] and the framework by Kahan et al. [19] in defining the estimands. The matched population will be used to estimate the intention-to-treat (ITT) effect. Handling of intercurrent

events, which are post-baseline events that might affect the interpretation of the results, are also specified. The estimands associated with the described in Table 2.

Table 2: Description of the estimands for testing the effectiveness of the Diabetes Alliance Program (DAP+) on hospitalisations compared to standard care in general practice.

Attribute	Average treatment effect on the treated (ATT) for the ITT population (effect of at least one exposure to DAP+ enhanced care)
Population	Adult patients with existing or new diagnosis of T2DM and recorded in Lumos who are active patients at general practices in NSW, Australia.
Treatment conditions	Intervention: Attending a DAP+-enhanced practice Comparison: Attending a non-DAP+ practice
Endpoint	Primary: • T2DM-related hospitalisations at 3 years. Secondary: • T2DM-related hospitalisations at 1 and 5 years. • Length-of-stay from T2DM-related hospitalisations at 1, 3, and 5 years. • T2DM-related potentially avoidable ED presentations at 1,3, and 5 years. • T2DM-related lower limb loss at 1, 3, and 5 years. • Metabolic marker levels at 1, 3, and 5 years. • Compliance to individualised diabetes assessment intervals. • All-cause mortality at 1, 3, and 5 years
Summary Measure	Incidence rate ratio Risk ratio Mean difference
Handling of intercurrent events	The intercurrent events of active attendance criteria violation will be handled using the treatment policy strategy: For all endpoints. analysis will be performed using the exposure assigned at baseline, regardless of actively attending individuals becoming inactive. The intercurrent event of treatment switching will be handled using the treatment policy strategy: For all endpoints. analysis will be performed using the exposure assigned at baseline, regardless of treatment switching (i.e., post-baseline switching from DAP+-enabled practice to non-DAP+ practice and vice versa). The intercurrent event of death during follow-up will be handled using the while-alive strategy: For all endpoints except all-cause mortality, patients who experience death during follow up will have their observations from the index date until the date of death included for analysis.

Primary Analyses

Causal analysis principles

An observational analogue of the ITT effect will be applied to the primary analysis. DAP+ exposure will be compared to the relevant comparator (standard care) using a propensity matched cohort.

FIGURE 1 PLACEHOLDER

Relevant covariates for creating the propensity matched cohort were identified using the directed acyclic graph (DAG) in Figure 1, which was informed by literature review[20-23] and clinical expertise. It was determined that treatment assignment is predominantly affected by geographic factors and general practice characteristics.

Factors that determine a patient's general practice of attendance are mainly their sociodemographic characteristics (IRSAD), their Modified Monash Classification (MMM), the extent of multimorbidities, and previous history of hospitalisations due to hyperglycaemia. In Australia, multimorbidity is more common in regional areas than in major cities[24]. As these factors may also be related to general health outcomes, they have the potential to be biasing pathways from intervention to the outcome. While BMI, age, and sex have been identified as belonging to the causal pathways, these factors are not required in the minimal adjustment set for closing the individual-level biasing paths. Adjustment for individual MMM, IRSAD, and comorbid conditions is sufficient to account for the individual-level bias identified in the DAG.

Additionally, individual factors alone do not determine whether they can receive DAP+-enhanced care as the practice they attend must have self-nominated to receive the DAP+ intervention i.e., for treatment exposure to occur at the individual level, self-nomination to the intervention must have also occurred at the general practice level. Practice self-nomination to the DAP+ program is more common among general practices outside of major cities as DAP+ is aimed towards, but not exclusive to, regional general practices[11]. Therefore, practice-level aggregates of patient (IRSAD), the MMM classification of the general practice, and operational characteristics i.e., high-frequency servicing, of the general practice were determined to be significant factors that affect practice self-nomination to DAP+. General practices that operate at high-frequency are defined as practices where >30% of attending patients visit at least 12 times in 2 years [20]. As these factors are also associated with health outcomes, they introduce a cluster-level biasing path upstream from the exposure to the outcome.

Statistical Methods and Analysis Plan

The goal of this approach is to estimate the causal effect of the general practice-targeted DAP+ intervention packaged T2DM-related hospitalisations among diabetes patients. 95% confidence intervals will be constructed using clustered bootstrap sampling and $p < 0.05$ (two-tailed) will be used to determine statistical significance.

A priori sample power calculation

In a previous evaluation of DAP+ (manuscript under review), the reported number of active patients that attended a DAP+-enhanced general practice was $N = 22706$ across 120 participating general practices. Presently, 50 DAP+-enhanced practices are captured in Lumos. Assuming an average of $n = 189$ diabetes per practice (22706/120), it would be expected that approximately $n = 9450$ patients that attend a DAP+-enhanced general practice can be obtained in Lumos. As the control unit pool available for matching includes the entirety of patients attending non-DAP+ enhanced general practices captured in Lumos (at least 600

general practices), it is expected that at least $n = 8977$ (95%) of treated patients can be matched to a control.

In Australia, the age-standardised rate of diabetes-as-principal-cause hospitalisations was estimated to be 49.8 per 1000 person-years among patients with type 1 and type 2 diabetes[25], or 0.05 per 1 person-year. Assuming the DAP+ intervention leads to a 50% reduction in T2DM-related hospitalisations at 3 years, simulations were conducted to estimate the power β to detect this difference in a two-arm sample of $N = 17954$ with a 1: 1 ratio of treated and controls.

The simulated data was generated as follows: outcome for both groups were sampled from a negative-binomial distribution that is parameterised by mean μ and variance σ^2. For the control group, 8977 draws from a negative binomial distribution with $\mu = 0.15$ and $\sigma^2 = 1.5\mu, 3u, 4u,$ and 5μ was performed to produce a simulated outcome averaging 0.15 admissions per three person-years, where variance at 5-fold the value of the mean was used as conservative estimate. Likewise for the treated group, 8977 draws from a negative binomial distribution with $\mu = 0.075$ and $\sigma^2 = 1.5\mu, 3u, 4u,$ and 5μ was performed to produce simulated outcomes averaging 0.075 admissions per three person-years with different variances.

GLMM simulation based power and precision analysis[26] were used to determine the power β when the intra-class correlation coefficient (ICC) was set to 0.05 and 0.10. Type-1 error α was set at 0.05. Simulations were performed 1000 times for each combination of σ^2 and ICC to obtain the mean β (Table 3). The expected sample size of $n = 8977$ is sufficient to detect a 50% decrease in T2DM-related hospitalisations with at least 85% power if such an intervention effect exists, providing σ^2 is no more than 4-fold of μ and the ICC is no larger than 0.05.

Table 3. Estimated power at different scales σ^2 and ICC, assuming n=8977 (N=17954).

	Power (β)	
σ^2 relative to μ	$ICC: 0.05$	$ICC: 0.10$
1.5μ	1.000	0.998
3μ	0.936	0.739
4μ	0.846	0.601
5μ	0.757	0.506

Descriptive statistics

Summary statistics of baseline characteristics will be stratified by treatment group and will include where available in the Lumos data asset; the age at study entry, sex, BMI, remoteness category, socioeconomic status, smoking status, comorbidities, and most recent measurements of T2DM-related metabolic markers in the last 6 months.

Summary measures will be mean and standard deviation (SD) or median and range, where appropriate for continuous variables, and frequencies and percentages for categorical variables.

Balancing cluster and individual confounders via propensity scores

The minimal adjustment variables set needed to identify the causal effect of the receiving the intervention include: practice MMM, practice aggregate IRSAD, practice high-frequency servicing, individual comorbidities, individual IRSAD, and individual Modified Monash Model. To further improve precision of estimates, adjustments BMI, sex, and age at the individual-level will be included.

Prior to individual matching, control and intervention clusters (i.e., general practices) will be matched by their MMM, IRSAD aggregates, frequency of servicing using exact matching i.e., matched general practices will have the exact same MMM, IRSAD aggregate, and frequency of servicing, and each intervention cluster can be matched with more than one control cluster. This first step ensures that the cluster level confounding from the given confounders will be balanced among intervention-control cluster matches.

After accounting for the cluster-level confounding by creating 'cluster-similar' groups, intervention-exposed individuals will be matched to control individuals only within these groupings. Individual matching will be performed via propensity scores. Propensity scores will be estimated using a logistic GEE, modeling individual exposure at baseline as the outcome and the confounder set as predictors and an exchangeable correlation structure among clusters. Each DAP+ participant will be allocated a 'best match' control who did not attend the DAP+ practice at baseline, according to the difference in propensity scores. The maximum allowed difference in propensity scores among matched dyads will be 0.2 pooled SD of the logit of the propensity scores. Each treated participant will be matched to one control without replacement. Unmatched treated and control units will be excluded.

Covariate balance will be assessed in terms of standardised mean differences and compared before and after propensity matching to determine whether balancing was successful. Interactions of variables and non-linear functional forms of continuous variables will be considered to iteratively improve covariate balance, as necessary.

Primary outcome

The primary outcome for T2DM-related hospitalisations at 3 years will be modelled as a Poisson or negative-binomial Bayesian hierarchical model using the propensity-matched sample to obtain incidence rate ratios (IRR). The Bayesian hierarchical model will contain a fixed effect parameter for treatment exposure and may contain additional parameters for adjustment variables. Within cluster and within individual repeated measures will be given a random effects structure. Very weak priors will be given to the fixed and random effect parameters.

Secondary outcomes

The secondary outcomes for T2DM-related hospitalisations at 1 and 5 years; T2DM-related potentially avoidable ED presentations at 1, 3, and 5 years; and length-of-stay from T2DM-related hospitalisations at 1, 3, and 5 years; will be modelled as a Poisson or negative-binomial Bayesian hierarchical models using the propensity-matched sample to obtain IRRs. The Bayesian hierarchical models will contain a fixed effect parameter for treatment exposure and may contain additional parameters for adjustment variables.

T2DM-related lower limb loss at 1, 3, and 5 years will be modelled as a Bayesian hierarchical logistic model to obtain relative risks (RR). The Bayesian hierarchical model will contain a fixed effect parameter for treatment exposure and may contain additional parameters for adjustment

variables. Within cluster and within individual repeated measures will be given a random effects structure.

Metabolic marker measurements will be modelled using a Bayesian hierarchical piece-wise linear model with 3 segments to obtain mean differences at 1, 3, and 5 years. The Bayesian hierarchical piece-wise linear model will contain a fixed effect parameter for treatment exposure, time as a continuous parameter for each segment, and parameters for the interaction of exposure and time. Segments will be partitioned on 0 to 1, 1 to 3, and 3 to 5 years after exposure. Within cluster and within individual repeated measures will be given a random effects structure.

Compliance to the annual cycle of care recommendations for regular measurements of diabetes metabolic markers will be modelled using Bayesian hierarchical binomial models. For each metabolic marker, compliance to the recommendations will be measured at 1, 3, and 5 years as binomial proportions of the number of months in compliance out 12, 36, and 60 months, respectively. The Bayesian hierarchical binomial models will contain a fixed effect parameter for treatment exposure and may contain parameters for additional adjustment variables. Within cluster and within individual repeated measures will be given a random effects structure.

All-cause mortality will be modelled using a Bayesian hierarchical pooled logistic model to obtain risk ratios at 1, 3, and 5 years. The Bayesian hierarchical pooled logistic model will contain a fixed effect parameter for treatment exposure and may contain parameters for additional adjustment variables. Within cluster measures will be given a random effects structure.

For all Bayesian models, uninformative/very weakly informative priors will be given to fixed and random effect parameters.

Sensitivity analysis

The effect of different specifications of the ICC and variance scales on the estimate and posterior density of the primary outcome treatment effect will be examined through a sensitivity analysis. Informative priors to ICC and variance scale components (reflecting the ICC and σ^2 in Table 3) will be incorporated and compared to the model that incorporate uninformative/very weakly informative priors for these parameters.

Ethics and dissemination

The Diabetes Alliance Program Plus has ethics approval from the Hunter New England Human Research Ethics Committee (2024/ETH01649), with approval registered with the University of Newcastle (R-2024-0073). The Lumos data asset is also ethically approved by the Population Health Services Research Ethics Committee (PHSREC; 2019/ETH00660), and DAP+ has received approval by their Governance Committee for the evaluation in this protocol. Any protocol changes during the course of the analysis due to issues arising with regard to data availability and quality will be documented and described in the final report. The study results will be disseminated to the Diabetes Alliance Program Plus, Hunter New England and Central Coast Primary Health Network, Hunter New England Local Health District, and the Colonial Foundation. The study will be submitted to a peer-reviewed academic journal.

DISCUSSION

The use of potentially preventable hospitalisations has been used to monitor the performance of primary health care systems as well as to evaluate the effectiveness of primary

care interventions in Australia and internationally [27]. It is demonstrated in the literature that the risk of hospital admissions among patients with T2DM is linked to elevated levels of HbA1c [28][29], as well as other markers that can readily be measured at the primary care setting, including elevated uACR, elevated systolic blood pressure, and lower HDL [29]. Given that the relationship between elevated HbA1c and macrovascular and microvascular complications have been identified since 2000 [30], the relationship between elevated HbA1c and increased hospitalisations should come as no surprise. Interventions that can improve control of these metabolic markers may reduce T2DM-related hospitalisations and other complications.

In the pilot study of DAP+ [11], it was demonstrated that DAP+ improved levels of diabetes-related metabolic markers, particularly HbA1c, among T2DM patients attending DAP+-enabled general practices. Given the link between metabolic markers and T2DM related complications, the findings of the study provide evidence that the DAP+ program may also improve longer-term outcomes for patients with T2DM, in part through the control of these metabolic risk factors. However, as the study was not designed to evaluate long-term endpoints, the effect of DAP+ on long-term outcomes remains an open and important question.

Ideally, questions about the effectiveness of an intervention would be assessed via an RCT. However, as the roll-out of the DAP+ program to the Hunter and New England region has been on-going since 2015, conducting a new RCT for the DAP+ program in the region may not be appropriate due to the possible spillover of the previous evaluation. While it may be possible to conduct the RCT in other health districts in Australia, the feasibility of this option is inhibited by the costs and logistics of implementing the DAP+ program from the ground up in another health service sector. Moreover, in absence of DAP+ Model of care, patients have limited access to metropolitan specialist care and are at risk of premature and progressive complications from under treated diabetes.

The DAP+ program has been progressively been rolled out to the Hunter New England region since 2015 and administrative health data from general practices in NSW is captured by the Lumos programs' [31] data linkage, yielding data that can be used for the long-term evaluation of the DAP+ program has long been accumulating. Using this existing observational data set with target trial emulation framework [15] to emulate an RCT is an attractive alternative to conducting a true RCT for the evaluation of the long-term effects of the DAP+ program. Existing work has demonstrated that emulated trials that use observational data to mimic RCTs can produce treatment effect estimates that are consistent with true RCTs [32].

While this protocol outlines the use of propensity score methods to balance important confounders, confounding bias cannot be completely accounted for as with any observational investigation [33-36] and remains an important limitation of the described study. In particular, confounding may be present if operating characteristics of each local health district and primary health network that general practices (clusters) are nested within, result in clinically different overall T2DM management. Confounding bias may be present if each of these health sectors operate significantly differently to their approach to T2DM management such that the outcomes of T2DM patients across these sectors are heterogenous, after accounting for geographic and socio-economic factors.

As inclusion to the Lumos programme is entirely via self-nomination, not every general practice in NSW is captured in Lumos. It is possible that sampling bias is present due to self-selection. However, the 2023 Lumos evaluation [37] reported an average of 91% representativeness of the Lumos cohort to the general NSW population in terms of general

demographic characteristics. While this does not necessarily suggest that sampling bias may be negligible, it still provides assurances of the external generalisability of the proposed investigation to the general NSW population.

The *a priori* power calculation using the anticipated sample size (treated arm $n = 8977$) suggests that the analysis could possess and average power ranging from 76% to >99% if the ICC = 0.05 and the variance of the primary outcome measure is less than 5-fold the mean of the primary outcome. ICC larger than the anticipated level will reduce power to 50% at the highest variance scale ($\sigma^2 = 5\mu$). It has been reported that the ICCs in T2DM primary care cluster RCTs for various outcomes is approximately 0.03 to 0.04 and using an ICC of 0.05 for planning is generally conservative[38 39]. Therefore, the actual ICC may be smaller than the anticipated level of 0.05. As the outcome models will be using the Bayesian framework, we will infer a treatment effect that is greater than 0 if 95% of the posterior density of the treatment effect is greater than 0.

Clinical practice is based on best available information. Regardless of the limitations stemming from unmeasured confounding from the use of observational data, this study will form the best available information about general practice centred T2DM care in predominantly rural and remote communities in NSW.

REFERENCES

1. Diabetes: Australian Facts: Australian Institute of Health and Welfare (AIHW); 2023 [updated 12 Dec 2023. Available from: https://www.health.nsw.gov.au/lumos/Factsheets/gp-activity-insight.pdf accessed Jun 2024.

2. Diabetes prevalence in adults: NSW Government (HealthStats NSW); [Available from: https://www.healthstats.nsw.gov.au/indicator?name=-dia-phs&location=LHD&view=Trend&measure=prevalence&groups=&filter=LHD,Hunter%20New%20England%20LHD accessed Jun 2024.

3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. *Phys Ther* 2008;88(11):1254-64. doi: 10.2522/ptj.20080020 [published Online First: 20080918]

4. Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social Determinants of Health and Diabetes: A Scientific Review. *Diabetes Care* 2020;44(1):258-79. doi: 10.2337/dci20-0053 [published Online First: 20201102]

5. Runciman WB, Hunt TD, Hannaford NA, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. *Med J Aust* 2012;197(2):100-5. doi: 10.5694/mja12.10510

6. Brown JB, Harris SB, Webster-Bogaert S, et al. The role of patient, physician and systemic factors in the management of type 2 diabetes mellitus. *Fam Pract* 2002;19(4):344-9. doi: 10.1093/fampra/19.4.344

7. Wan Q, Harris MF, Davies GP, et al. Cardiovascular risk management and its impact in Australian general practice patients with type 2 diabetes in urban and rural areas. *Int J Clin Pract* 2008;62(1):53-8. doi: 10.1111/j.1742-1241.2007.01604.x [published Online First: 20071010]

8. Paul CL, Piterman L, Shaw J, et al. Diabetes in rural towns: effectiveness of continuing education and feedback for healthcare providers in altering diabetes outcomes at a population level: protocol for a cluster randomised controlled trial. *Implement Sci* 2013;8:30. doi: 10.1186/1748-5908-8-30 [published Online First: 20130313]

9. Factsheet: Your diabetes annual cycle of care: National Diabetes Services Scheme (NDSS); 2022 [Available from: https://www.ndss.com.au/wp-content/uploads/fact-sheets/fact-sheet-your-diabetes-annual-cycle-of-care.pdf accessed Jun 2024.

10. Management of type 2 diabetes: A handbook for general practice: Royal Australiasian College of General Practitioners (RACGP); 2020 [Available from: https://www.racgp.org.au/getattachment/41fee8dc-7f97-4f87-9d90-b7af337af778/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx accessed Jun 2020.

11. Acharya S, Philcox AN, Parsons M, et al. Hunter and New England Diabetes Alliance: innovative and integrated diabetes care delivery in general practice. *Aust J Prim Health* 2019;25:219-43. doi: 10.1071/py18179

12. Harris ML, Kuzulugil D, Parsons M, et al. "They were all together ... discussing the best options for me": Integrating specialist diabetes care with primary care in Australia. *Health Soc Care Community* 2021;29(5):e135-e43. doi: 10.1111/hsc.13254 [published Online First: 20201214]

13. Taylor R, Acharya S, Parsons M, et al. Australian general practitioners' perspectives on integrating specialist diabetes care with primary care: qualitative study. *BMC Health Serv Res* 2023;23(1):1264. doi: 10.1186/s12913-023-10131-4 [published Online First: 20231116]

14. Lee CM, Colagiuri R, Magliano DJ, et al. The cost of diabetes in adults in Australia. *Diabetes Res Clin Pract* 2013;99(3):385-90. doi: 10.1016/j.diabres.2012.12.002 [published Online First: 20130105]

15. Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *Am J Epidemiol* 2016;183(8):758-64. doi: 10.1093/aje/kwv254 [published Online First: 20160318]

16. Lumos Data Governance Framework: Ministry of Health (MoH); 2021 [updated 01 Sept 2021. Available from: https://www.health.nsw.gov.au/lumos/Publications/data-governance-framework.pdf accessed Jun 2024.

17. Health AIo, Welfare. Indicators for the Australian National Diabetes Strategy 2016–2020: data update. Canberra: AIHW, 2020.

18. Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials E9(R1): International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2019 [updated Nov 2019. Available from: https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf accessed Jun 2024.

19. Kahan BC, Hindley J, Edwards M, et al. The estimands framework: a primer on the ICH E9(R1) addendum. *BMJ* 2024;384:e076316. doi: 10.1136/bmj-2023-076316 [published Online First: 20240123]

20. General practice activity can affect hospital visits: The Lumos Program; 2021 [updated Dec 2021. Available from: https://www.health.nsw.gov.au/lumos/Factsheets/gp-activity-insight.pdf accessed Jun 2024.

21. Phillips A. Health status differentials across rural and remote Australia. *Aust J Rural Health* 2009;17(1):2-9. doi: 10.1111/j.1440-1584.2008.01029.x

22. Britt HC, Harrison CM, Miller GC, et al. Prevalence and patterns of multimorbidity in Australia. *Med J Aust* 2008;189(2):72-7. doi: 10.5694/j.1326-5377.2008.tb01919.x

23. Glenister KM, Guymer J, Bourke L, et al. Characteristics of patients who access zero, one or multiple general practices and reasons for their choices: a study in regional Australia. *BMC Fam Pract* 2021;22(1):2. doi: 10.1186/s12875-020-01341-4 [published Online First: 20210102]

24. Health AIo, Welfare. Multimorbidity. Canberra: AIHW, 2024.

25. Comino EJ, Harris MF, Islam MD, et al. Impact of diabetes on hospital admission and length of stay among a general population aged 45 year or more: a record linkage study. *BMC Health Serv Res* 2015;15(1):12. doi: 10.1186/s12913-014-0666-2 [published Online First: 20150122]

26. Stroup WW. Generalized linear mixed models: modern concepts, methods and applications: CRC press 2012.

27. A guide to the potentially preventable hospitalisations indicator in Australia: Australian Commision on Safety and Quality in Health Care; 2017 [updated March 2017. Available from: https://www.safetyandquality.gov.au/sites/default/files/migrated/A-guide-to-the-potentially-preventable-hospitalisations-indicator-in-Australia.pdf accessed Jun 2024.

28. Bo S, Ciccone G, Grassi G, et al. Patients with type 2 diabetes had higher rates of hospitalization than the general population. *J Clin Epidemiol* 2004;57(11):1196-201. doi: 10.1016/j.jclinepi.2004.02.015

29. Tomlin AM, Dovey SM, Tilyard MW. Risk factors for hospitalization due to diabetes complications. *Diabetes Res Clin Pract* 2008;80(2):244-52. doi: 10.1016/j.diabres.2007.12.017 [published Online First: 20080219]

30. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321(7258):405-12. doi: 10.1136/bmj.321.7258.405

31. Correll P, Feyer AM, Phan PT, et al. Lumos: a statewide linkage programme in Australia integrating general practice data to guide system redesign. *Integr Healthc J* 2021;3(1):e000074. doi: 10.1136/ihj-2021-000074 [published Online First: 20210516]

32. Wang SV, Schneeweiss S, Initiative R-D, et al. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. *JAMA* 2023;329(16):1376-85. doi: 10.1001/jama.2023.4221

33. Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. *Am J Epidemiol* 2007;166(6):646-55. doi: 10.1093/aje/kwm165 [published Online First: 20070705]

34. Howards PP. An overview of confounding. Part 1: the concept and how to address it. *Acta Obstet Gynecol Scand* 2018;97(4):394-99. doi: 10.1111/aogs.13295 [published Online First: 20180208]

35. Verbeek JH, Whaley P, Morgan RL, et al. An approach to quantifying the potential importance of residual confounding in systematic reviews of observational studies: A GRADE concept paper. *Environ Int* 2021;157:106868. doi: 10.1016/j.envint.2021.106868 [published Online First: 20210913]

36. Arah OA. Bias Analysis for Uncontrolled Confounding in the Health Sciences. *Annu Rev Public Health* 2017;38:23-38. doi: 10.1146/annurev-publhealth-032315-021644 [published Online First: 20170106]

37. Lumos Evaluation Report 3: The Lumos Program; 2023 [cited 2024 June]. Available from: https://www.health.nsw.gov.au/lumos/Publications/lumos-evaluation-report-3.pdf.

38. Lee YL, Lim YMF, Law KB, et al. Intra-cluster correlation coefficients in primary care patients with type 2 diabetes and hypertension. *Trials* 2020;21(1):530. doi: 10.1186/s13063-020-04349-4 [published Online First: 20200616]

39. Martin J, Girling A, Nirantharakumar K, et al. Intra-cluster and inter-period correlation coefficients for cross-sectional cluster randomised controlled trials for type-2 diabetes in UK primary care. *Trials* 2016;17:402. doi: 10.1186/s13063-016-1532-9 [published Online First: 20160815]